LIB Therapeutics is a privately-held, late-stage biopharmaceutical company dedicated to bringing novel, safe and convenient subcutaneous and oral PCSK9 inhibitors to the millions of patients with cardiovascular disease and the 30 million individuals with familial hypercholesterolemia (FH), who require additional large reductions in low density lipoprotein-cholesterol (LDL-C) despite maximally tolerated statins and other lipid lowering agents.
Lerodalcibep is a novel, third-generation, PCSK9 inhibitor in development to overcome the limitations of current low density lipoprotein-cholesterol (LDL-C) lowering treatments, including statins and ezetimibe, to achieve the lower LDL-C targets in recently updated national and international guidelines to treat and prevent cardiovascular disease (CVD). Lerodalicibep is being developed as a convenient, small-injection volume, once-monthly dose with long-ambient stability. Combined with sustained LDL-C reductions demonstrated in clinical trials, lerodalcibep is expected to expand treatment options for the millions of patients around the world with atherosclerotic cardiovascular disease (ASCVD), and those at very high and high risk for ASCVD, including the 30 million individuals with more severe inherited high-cholesterol called familial hypercholesterolemia (FH).
We are developing Lerodalcibep, a novel, third-generation, PCSK9 inhibitor as a convenient, single, once-monthly subcutaneous dose for patient convenience.
LIB Therapeutics was founded in 2015 by an experienced team that recognized the need to achieve greater reductions in LDL-C — despite patients being on maximally tolerated statins and other lipid lowering agents.
Cardiovascular disease is the #1 global cause of death. 103M patients worldwide in 2020 had clinically significant ASCVD that required treatment. Cinically-significant ASCVD patient population will increase to 137M patients by 2030. We aim to help patients achieve their LDL-C goal — where lower is better.